216 related articles for article (PubMed ID: 10697982)
1. [Clinical experience with raloxifene].
Szúcs J; Pávó I; Jurida N
Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
[TBL] [Abstract][Full Text] [Related]
2. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Hart W; Netelenbos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
[TBL] [Abstract][Full Text] [Related]
3. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
4. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
5. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene for the treatment and prevention of breast cancer?
Pappas SG; Jordan VC
Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
[TBL] [Abstract][Full Text] [Related]
7. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
8. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
10. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
11. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
12. [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].
Inoue D
Clin Calcium; 2010 Mar; 20(3):331-8. PubMed ID: 20190362
[TBL] [Abstract][Full Text] [Related]
13. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
14. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
15. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene.
Gass ML
South Med J; 1999 Nov; 92(11):1120-3. PubMed ID: 10586846
[No Abstract] [Full Text] [Related]
17. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
18. [SERM--selective estrogen receptor modulators].
Kønig KB; Eiken PA; Schwarz P
Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
Riggs BL; Hartmann LC
N Engl J Med; 2003 Feb; 348(7):618-29. PubMed ID: 12584371
[No Abstract] [Full Text] [Related]
20. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
